Measuring the Amount of Methadone or Morphine in the Blood of Neonates, Infants & Children After Cardiac Surgery.
Status: | Archived |
---|---|
Conditions: | Chronic Pain |
Therapuetic Areas: | Musculoskeletal |
Healthy: | No |
Age Range: | Any |
Updated: | 7/1/2011 |
Start Date: | March 2010 |
End Date: | April 2011 |
A Randomized, Double-blind, Controlled, Multi-site Study of the Pharmacokinetics and Pharmacodynamics of Methadone vs. Morphine During Mechanical Ventilation Following Cardiac Surgery in Neonates, Infants and Children
Study Population:
Neonates, infants and children from birth to 5 years of age undergoing cardiac surgery with
CPB.
The use of methadone to provide analgesia may be increasing due to advantages compared to
other commonly used opioid analgesic drugs. While efficacy of methadone has been reported in
adults, there is a paucity of information in neonates and infants. In the latter population,
fentanyl and morphine are most commonly used for opioid analgesia following major surgery,
while methadone is frequently used for weaning of opioid dependent and tolerant patients, in
spite of the paucity of knowledge of methadone pharmacology in this population. There are
several clinical problems associated with fentanyl and morphine, and methadone may offer
superior efficacy with fewer side effects than these agents. We propose to study the
pharmacokinetics (PK) and pharmacodynamics (PD) of methadone in neonates and infants in the
intensive care unit following cardiac surgery.
Treatment:
Fentanyl will be administered for intraoperative analgesia by the treating anesthesiologist
in a dose range of 25 - 50 mcg/kg. No other intraoperative opioids will be given.
Subjects will receive intravenous methadone or morphine ("study drug") delivered by an
initial IV "bolus" injection followed by a nurse-administered patient controlled analgesia
(PCA) device for postoperative pain for a period of 24 hours. The initial dose of study drug
will be 0.2 mg/kg IV administered following admission to the ICU after surgery. The study
drug will then be given at a dose of 0.035 mg/kg IV as needed q30min via PCA. The study drug
may be increased or decreased in increments of 20-25% according to the discretion of the
investigator as needed to maintain a FLACC pain assessment tool < 4. Subjects will also
receive lorazepam 0.025 mg/kg IV q2hr as needed for agitation as indicated by specific
criteria. The study drug will be discontinued after 24 hours to facilitate "wash out"
sampling and determination of elimination half-life. Beginning at 24 hours, fentanyl will be
used for analgesia at an equianalgesic dose to be determined by the investigator based upon
the current PCA "study drug" dose.
Measurements and Monitoring:
- Blood samples will be obtained for measurement of concentrations of methadone
(methadone group) and morphine and its metabolites, morphine-3-glucuronide and
morphine-6-glucuronide (morphine group), prior to administration of initial bolus dose
(t = 0) and t = 5 min, 15 min, 30 min, 60 min, 2 hrs, 4 hrs and 6 hrs; thereafter,
blood samples will be obtained for measurement every 6 hrs for up to 90 hrs according
to availability of vascular access for phlebotomy.
- Continuous monitoring: temperature (rectal), electrocardiogram, heart rate, systemic
arterial blood pressure, central venous blood pressure, respiratory rate, oxygen
saturation (pulse oximetry)
- Intermittent recording (q1hr): urine output
- Lab Tests (at baseline[prior to study procedures] and 24 hours after initial dose of
study medication): arterial blood gas tensions, arterial lactate, Hb/Hct, BUN/Cr,
glucose, AST, ALT
- 12 lead ECG at hour 24 for determination of QTc.
- The Faces, Legs, Activity, Cry, Consolability (FLACC) Scale recoded every hour, and
preceding every study medication PCA dose for 24 hours.
- Subject follow up at 90 hours to record time of extubation, re-intubation if necessary,
and reason for re-intubation.
Primary Endpoints: Pharmacokinetics of methadone and morphine, including its metabolites
(morphine-3-glucuronide and morphine-6-glucuronide)
Secondary Endpoints:
- Pain scores (FLACC) during the 24 hours study period
- Amount of study drug administered during the 24-hour dosing period
- Changes in heart rate, systemic arterial blood pressure and laboratory test values
We found this trial at
3
sites
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
Portland, Oregon 97239
503 494-8311
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
Click here to add this to my saved trials
University of Colorado, Boulder As the flagship university of the state of Colorado, CU-Boulder is...
Click here to add this to my saved trials
Stanford university Hospital and Clinics Throughout our history, we have pioneered medical advances that save...
Click here to add this to my saved trials